NCT03871257: An ongoing trial by National Cancer Institute (NCI)
This trial is ongoing. It must report results 2 years, 6 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03871257 |
|---|---|
| Title | A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 15, 2020 |
| Completion date | Dec. 31, 2027 |
| Required reporting date | Dec. 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 9, 2026 |
| Days late | None |